Clinical Research Directory
Browse clinical research sites, groups, and studies.
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Sponsor: Inova Health Care Services
Summary
The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Key Details
Gender
All
Age Range
18 Years - 98 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2026-09-04
Completion Date
2030-12-30
Last Updated
2026-09-21
Healthy Volunteers
No
Interventions
Valproic Acid (VPA)
Day 1 40mg/kg/dose PO BID and simvastatin at 40mg PO daily
Irinotecan
D2 irinotecan 180mg/m2 IV and VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily
Simvastatin
Day3-21 Continuous simvastatin starting at 40mg daily PO
Locations (1)
Inova Schar Cancer
Fairfax, Virginia, United States